The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|May 13, 2020
Catalent Enters into Agreement with Ennaid for Oral COVID-19 Treatment
Author(s)Pharmaceutical Technology Editors
Under the terms of the agreement, Catalent will develop a powder-in-capsule formulation of Ennaid’s ENU200 program at its site in San Diego, CA.
Advertisement
Catalent announced on May 13, 2020 that it is entering into an agreement with Ennaid Therapeutics, a pharmaceutical company located in Alpharetta, GA, to further develop Ennaid’s ENU200 program, an oral, antiviral treatment for COVID-19.
Under the terms of the agreement, Catalent will develop a powder-in-capsule formulation of ENU200 at its site in San Diego, CA, a company press release said. The program was selected as a potential COVID-19 treatment candidate after a bioinformatic search for in-silico identification of previously approved chemical compounds were found to block coronavirus proteins.
“During this pandemic we have seen that numerous companies are looking to repurpose existing antiviral drugs to target COVID-19, and we are supporting our development partners in reacting quickly and effectively to manufacture material for clinical trials,” said Jonathan Arnold, president, Oral and Specialty Delivery at Catalent, in the press release. “Our experience with similar formulation and manufacturing processes and overcoming scale up challenges with roller compaction has meant that we are able to rapidly deliver Ennaid’s demand for drug product in a matter of weeks.”
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Advertisement
Advertisement